Literature DB >> 341692

Passive immunization against hepatitis B: a review of recent studies and comment on current aspects of control.

J E Maynard.   

Abstract

Several independent studies suggest that both hepatitis B immune globulin (HBIG) made from plasma pools containing high titers of anti-HBs and standard immunoglobulin (IG) containing some anti-HBs may be effective for pre- and post-exposure prophylaxis of hepatitis B. Based on a synthesis of current data, it seems reasonable to recommend HBIG for the post-exposure prophylaxis of individuals sustaining accidental needle stick or mucosal exposure to blood known to contain hepatitis B surface antigen (HBsAg). If HBIG is unavailable there is also reason to expect that administration of standard IG which contains some anti-HBs may confer benefit. Although available data regarding prophylaxis of infants born to mothers with HBsAg positive hepatitis at time of delivery are insufficient to warrant firm recommendations on globulin administration, a temporary set of guidelines supporting use of either HBIG or standard IG containing some anti-HBs seems warranted in view of the serious implications for induction of the HBsAg chronic carrier state in infancy. Because appropriate environmental control measures may significantly reduce the transmission of hepatitis B in certain endemic settings such as hemodialysis units or homes for the mentally retarded, IG prophylaxis in these surroundings cannot be routinely recommended. Since current data show no evidence for superiority of HBIG over standard IG in these settings, and because there is some evidence that use of lower anti-HBs titer globulins may provide for acquisition of passive-active immunity, it seems reasonable to suggest that if IG is to be used for pre-exposure prophylaxis, the material to be used should be standard IG containing some anti-HBs.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 341692     DOI: 10.1093/oxfordjournals.aje.a112520

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  6 in total

Review 1.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

2.  The HBsAg-Positive Patient: Implications and a Guide to Management.

Authors:  R P Larke
Journal:  Can Fam Physician       Date:  1979-03       Impact factor: 3.275

3.  Serological markers for hepatitis types A and B among U.S. Arym soldiers, Germany.

Authors:  J J James; L Smith
Journal:  Am J Public Health       Date:  1979-12       Impact factor: 9.308

4.  [Experiments for the development of a hepatitis B vaccine: immunogenicity of HBsAg in guinea pigs (author's transl)].

Authors:  B Stamm; W Gerlich; R Thomssen
Journal:  Med Microbiol Immunol       Date:  1979-05-15       Impact factor: 3.402

5.  Impact of technological developments on infectious disease epidemiology: Lessons from the first 100 years of AJE.

Authors:  Betsy Foxman; Shruti Mehta
Journal:  Am J Epidemiol       Date:  2022-03-31       Impact factor: 5.363

6.  Retrospective Review of Documentation Practices of Hepatitis B Immunoglobulin, Birth Dose, and Vaccination at the Hospital of Birth, in Thai Nationals and Migrants in Northern Thailand.

Authors:  M Bierhoff; Kanokporn Pinyopornpanish; Kanokwan Pinyopornpanish; F Tongprasert; Arunrot Keereevijit; M Rijken; C S Chu; F Nosten; J Perfetto; M van Vugt; R Mcgready; C Angkurawaranon
Journal:  Open Forum Infect Dis       Date:  2019-12-07       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.